MARKET

DMAC

DMAC

Diamedica Therapeutics Inc
NASDAQ
6.86
-0.03
-0.44%
Closed 16:10 03/25 EDT
OPEN
6.92
PREV CLOSE
6.89
HIGH
7.18
LOW
6.75
VOLUME
198.28K
TURNOVER
0
52 WEEK HIGH
10.42
52 WEEK LOW
3.190
MARKET CAP
367.55M
P/E (TTM)
-9.5623
1D
5D
1M
3M
1Y
5Y
1D
DIAMEDICA THERAPEUTICS TO REPORT FOURTH QUARTER 2025 FINANCIAL RESULTS AND PROVIDE A BUSINESS UPDATE MARCH 31, 2026
Reuters · 3d ago
Weekly Report: what happened at DMAC last week (0316-0320)?
Weekly Report · 3d ago
Weekly Report: what happened at DMAC last week (0309-0313)?
Weekly Report · 03/16 09:32
Analysts Offer Insights on Healthcare Companies: Savara (SVRA), Codexis (CDXS) and Diamedica Therapeutics (DMAC)
TipRanks · 03/09 14:20
Weekly Report: what happened at DMAC last week (0302-0306)?
Weekly Report · 03/09 09:33
Analysts Offer Insights on Healthcare Companies: Compass Therapeutics (CMPX), Diamedica Therapeutics (DMAC) and Veeva Systems (VEEV)
TipRanks · 03/05 14:30
DiaMedica Therapeutics Gets No Objection Letter From Health Canada For Its Clinical Study Application Of DM199 In Phase 2 Trial In Participants With Early-Onset Preeclampsia
Benzinga · 03/05 12:38
Health Canada Clears DiaMedica Phase 2 DM199 Preeclampsia Trial
Reuters · 03/05 12:35
More
About DMAC
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people suffering from preeclampsia (PE) and acute ischemic stroke (AIS). The Company’s lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of pre-eclampsia, acute ischemic stroke and other vascular diseases. DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for preeclampsia and acute ischemic stroke. KLK1 is a serine protease enzyme that is involved in the regulation of diverse physiological processes via a molecular mechanism that increases the production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factors. In the treatment of preeclampsia, DM199 is intended to lower blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta.

Webull offers DiaMedica Therapeutics Inc stock information, including NASDAQ: DMAC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DMAC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DMAC stock methods without spending real money on the virtual paper trading platform.